塞拉斯纳米乳液可以选择性地调节突巨细胞的亡,以缓解类风湿性关节炎
Chenglong Li1,2, Yan Li3, Qing Zeng1,2
1Department of Pharmacy, Deyang People's Hospital, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Deyang, China.
Journal of drug targeting
|May 7, 2024
概括
新的纳米乳液向突巨细胞治疗类风湿性关节炎 (RA). 这种方法促进巨细胞亡,通过减少关节炎症和骨质侵蚀,为RA提供有效和低毒性治疗.
科学领域:
- 纳米技术 纳米技术
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特征是结膜炎炎症.
- 突性巨细胞的失调的增殖和亡是RA发病的关键驱动因素.
- 向巨细胞以诱导亡为 RA 提供了一个潜在的治疗策略.
研究的目的:
- 设计和评估用于 RA 治疗的含有 celastrol (SR-CLTNEs) 的突性巨细胞向纳米乳液.
- 调查SR-CLTNEs在向巨细胞和减少关节炎症和骨质侵蚀中的疗效,在RA的小鼠模型中.
主要方法:
- 硫酸盐 (DS) 功能化纳米乳液 (SR-CLTNEs) 的开发,以准巨细胞上的食尸体受体A (SR-A).
- 在体内和体外研究使用原诱导关节炎小鼠模型来评估向效率,巨细胞亡和治疗效果.
- 使用光标记量化巨细胞向效率的量化.
主要成果:
- 与非向纳米乳液和免费药物 (20.53% vs 13.93% 和 9.8%) 相比,SR-CLTNEs在RA关节中对突巨细胞具有更高的向效率.
- SR-CLTNEs有效地诱导了巨细胞的亡,重新平衡了增殖和亡.
- 用SR-CLTNEs治疗显著减少关节炎症和骨质侵蚀,具有高效率和低毒性.
结论:
- SR-CLTNEs代表了一种针对类风湿性关节炎的新有效的纳米治疗方法.
- 通过塞拉斯特载纳米乳液通过SR-A向巨细胞显示出对RA的显著治疗潜力.
- 这一战略为开发具有更高效率和安全性的RA先进治疗方法提供了一个有前途的途径.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K


